top of page

Special Interest Groups

Iraqi League for Bone Joint Health
Special Interest Groups
(ILBJH SIGs)

Screenshot 2023-04-29 104324.png
1.png

Rheumatology in Iraq is now growing and the scientific meeting has been held every year. Therefore, it is important to create our sustainable scientific interactions among Rheumatologists from various regions of Iraq in each field of Rheumatology.


Therefore, Iraqi League for Bone and Joint Health decided to establish Special Interest Groups (SIGs) in the following fields: Inflammatory Arthritis, Connective Tissue Diseases, Osteoporosis and Bone Diseases & Medical Rehabilitation.


Other fields could be identified and established in future as the needs arise, in consultation with the Scientific Committee and final approval obtained from ILBJH Board of Directors.


Members of SIGs are genuinely interested clinicians in the area of the SIG and their selection based on nomination from different governorates.


In principle, the members of each SIG should discuss and determine their activities together with their steering committee. Each activity will be reviewed and approved by ILBJH Board ofDirectors. 

Screenshot 2023-04-29 104512.png

Iraqi League for Bone Joint Health
Inflammatory Arthritis Special Interest Group

Mission

To raise awareness among patients with IA and to bring experts in rheumatology fields together to share expertise & facilitate best practice exchange and ongoing medical development.

 

Objectives

The aim of IA SIG is to create our sustainable scientific interactions among rheumatologists from various region of Iraq in each field related to inflammatory arthritis.

 

Plan

  1. Patient empowerment & awareness (world day celebration, themes & flyers).

  2. Education of physicians: Educational online program targeting fellows, residents & post graduate students through website or face book of ILBJH possibly at regular weekly or monthly interval using the following materials:

    • Publishing case scenarios with unusual, challenging, unsolved presentation.

    • Open a scheduled discussion room for difficult cases, and if possible, engaging an expert rheumatologist.

    • Reporting unusual / rare side effects of c/b DMARDs.

    • Periodic meeting of the group on regular schedule for scientific purposes.

    • Provide the rheumatologists with the opportunities for accessing the latest updates, guidelines, publications that are presented in annual meetings.

  3. Formulation of management algorithm or guideline of each disease.

  4. Development of a registry (creating unified database of biologic agent users in Iraq, starting

  5. registration of patients with IA).

  6. Development of research collaboration and motivation in these fields.

  7. SIG publication.

bottom of page